Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 8;9:9852. doi: 10.1038/s41598-019-46293-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Comparison of the safety and efficacy scores associated to drug targets found for AD and T2D. Scatter plots showing the safety and efficacy scores for the top 50 targets selected by OT and by a weighted scoring system integrating the efficacy (w = 0.5) and safety (w = 0.5) estimates compiled with the new methods. The safety score was derived using a harmonic sum on the ADR, centrality and onco-driven scores. The efficacy score instead was obtained by applying the E_hs ensemble strategy. Targets with known safety concerns are highlighted with the red color. (a) Top 50 targets for T2D and (b) AD identified by each approach.